The Dual PPARα/γ Ligand TZD18 Inhibits Cell Growth and Induces Apoptosis in Human Bcr-Abl Positive CML Cell Lines >in Vitro
Peiying Yang,Diana Chan,Mary Vijjeswarapu,Carrie Cartwright,Lorenzo Cohen,Zhiqiang Meng,Luming Liu,Robert A. Newman
IF: 11.2
2006-01-01
Cancer Research
Abstract:3852 Chan su, the dried toad venom or the dried secretion from the skin glands of Bufo bufo gargarizans Cantor or B. melanotictus Schneider, has long been used as a therapeutic agent for cancer treatment in China and other Asian countries. Huachansu, an injectable form of Chan su, is a sterilized hot water extract of dried toad skin. Since 1991, huachansu has been officially approved as a regimen for treatment of cancer in China. However, the selectivity and mechanism of anti-cancer activity of huachansu have not been fully elucidated. The goals of our current study were to investigate the cytotoxicity of huachansu alone as well as the polar and non-polar compartments of huachansu and cardiac glycosides derived from huachansu against various cancer cells. In addition, we explored mechanisms associated with this extract’s antiproliferative activity. The inhibitory effects of three different lots of huachansu were tested in four different human cell lines including hepatoma (Hep 3B), colon (HT29), pancreatic (Panc-1) and melanoma (BRO) cells. The relative growth inhibitory activity on the growth of cancer cells for all three lots of huachansu was ranked as Panc-1 > HT29 > BRO > Hep3B cells. The inhibitory effect of the non-polar fraction (lipid soluble) of huachansu was much stronger than that of the polar compartment (water soluble) with IC50 of 1.75 mg /ml versus 31.25 mg (raw material)/ml, respectively. These data suggest that huachansu’s antitumor activity is mainly attributed to the lipid-soluble components. Because cardiac glycosides are one of the lipid soluble components in huachansu, we next tested the relative cytotoxicity of three different cardiac glycosides derived from huachansu, including bufalin, cinobufagin, and resibufogenin against BRO cells. The IC50 values of bufalin, cinobufagin, and resibufogenin in BRO cells were 16.7, 20.1 and 700 ng/ml, respectively. When BRO cells were treated with huachansu (1 to 25 mg/ml) for 24 hr, huachansu induced cell cycle arrest in the G2/M-phase. Furthermore, huachansu as well as bufalin down-regulated Bcl-2 expression, yet up-regulated BAX protein in BRO cells in a concentration-dependent manner. In addition, our preliminary data also demonstrated that huachansu (10 mg/ml) significantly reduced B23 (neucleophosmin), pAKT and STAT3 expression. Concomitantly, it up-regulated several cell signaling pathways such as SRC, MAPK, and Raf, which is attributed to the stress-mediated cell response of huachansu cardiac glycosides. Taken together, these results suggest that cardiac glycosides, such as bufalin, are responsible for huachansu induced cell death in BRO cells. Whether other components in huachansu also contribute to its anti-proliferative activity requires further investigation. This research was supported in part by NCI R21 CA108084-01, International Center of TCM for Cancer.